GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus
2 other identifiers
observational
1,800
10 countries
10
Brief Summary
This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2010
Shorter than P25 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 23, 2013
CompletedFirst Posted
Study publicly available on registry
September 25, 2013
CompletedApril 27, 2017
April 1, 2017
6 months
September 23, 2013
April 25, 2017
Conditions
Outcome Measures
Primary Outcomes (2)
Frequency of insulin omission/non-adherence
In the past 30 days prior to the day when responding to the survey (patient survey)
Reasons for insulin omission/non-adherence reported by patient and physician
Day 1 (when responding to the survey)
Secondary Outcomes (1)
Impact of insulin treatment on life domains (patient survey)
Day 1 (when responding to the online questionnaire)
Study Arms (2)
Patients with diabetes
Physicians
Interventions
Survey conducted through computer-assisted telephone interviewing.
Eligibility Criteria
Insulin treated patients with diabetes (type 1 or 2), and physicians involved in the treatment, management of diabetes and care of patients with diabetes.
You may qualify if:
- PATIENTS WITH DIABETES:
- Age 18 years or older
- Treated with insulin
- Type 1 or Type 2 diabetes
- PHYSICIANS:
- In practice for more than 1 year since completing residency
- See a minimum number of patients with diabetes per week (primary care physicians 5, specialists 10)
- Initiate insulin treatment for patients with diabetes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Novo Nordisk A/Slead
Study Sites (10)
Novo Nordisk Investigational Site
Princeton, New Jersey, 08540, United States
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, 100004, China
Novo Nordisk Investigational Site
Paris La Défense Cedex, 92932, France
Novo Nordisk Investigational Site
Mainz, 55127, Germany
Novo Nordisk Investigational Site
Bangalore, 560001, India
Novo Nordisk Investigational Site
Tokyo, 1000005, Japan
Novo Nordisk Investigational Site
Moscow, 119330, Russia
Novo Nordisk Investigational Site
Madrid, 28033, Spain
Novo Nordisk Investigational Site
Istanbul, 34335, Turkey (Türkiye)
Novo Nordisk Investigational Site
Crawley, RH11 9RT, United Kingdom
Related Publications (1)
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012 May;29(5):682-9. doi: 10.1111/j.1464-5491.2012.03605.x.
PMID: 22313123RESULT
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Global Clinical Registry (GCR, 1452)
Novo Nordisk A/S
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2013
First Posted
September 25, 2013
Study Start
March 1, 2010
Primary Completion
September 1, 2010
Study Completion
September 1, 2010
Last Updated
April 27, 2017
Record last verified: 2017-04